Single MS injection
October 19, 2010
MERCK Serono has released the
results of its RebiDose User Trial,
which trialled the new single use
pre-filled pen device on MS
patients.
Filled with (interferon beta-1a), a
disease modifying drug for the
treatment of relapsing MS, the pen
was designed to simplify the selfinjection
process.
72% of the 109 trial participants
reported that they would continue
to use RebiDose if it became
available.
Trial participants also reported
that, over the 12-week testing
period, the pen had an error rate
of 0.4%, and that overall it was
“easy” or “very easy to use”.
Currently approved for use in the
EU and Australia, Merck now plans
to roll out RebiDose in the US by
the end of the year, followed by
launches on a “country-bycountry”
basis.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Oct 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Oct 10
